摘要
目的探讨低分子肝素治疗急性脑梗死的临床疗效和安全性。方法选择我院收治的60例急性脑梗死患者的临床资料,对照组30例采用常规治疗,观察组30例在对照组治疗的基础上加用低分子肝素进行治疗,比较2组患者的临床疗效和安全性。结果治疗后,观察组总有效率93.33%,明显高于对照组,且差异具有统计学意义(P<0.05),同时,观察组患者的Fg、PT、血小板黏附率等指标也出现了较为显著的改善,且与对照组比较,差异均具有统计学意义(P<0.05),而观察组患者治疗前后的出、凝血时间和部分凝血活酶时间基本相当,差异无统计学意义(P>0.05)。结论低分子肝素治疗急性脑梗死患者具有十分显著的疗效,其安全可靠,有利于促进患者预后恢复,值得临床推广和应用。
Objective To evaluate the clinical efficacy and safety of low molecular weight heparin in the treatment of acute cerebral infarction. Methods Totally 60 patients with acute cerebral infarction were divided into two groups, including control group of 30 patients with conventional therapy and observation group of 30 patients with low molecular weight heparin treat- ment. The clinical efficacy and safety of two groups were compared. Results After treatment, the total effective rate of obSer- vation group was 93.33 %, which was significantly higher than control group, the difference was statistically significant （P〈 0.05）, and the indicators of Fg, PT, platelet adhesion rate had significant improvement in the observation group than that of control group, and the differences had statistical significance （P〈0.05）, while BT, CT and KPTT didn＇t change, and the difference wasn＇t statistically significant （P〈0.05）. Conclusion The low molecular weight heparin in the treatment of patients with acute cerebral infarction has a very significant effect. It is safe and reliable, and is worthy of extensive promotion and ap- plication.
出处
《中国实用神经疾病杂志》
2013年第10期9-11,共3页
Chinese Journal of Practical Nervous Diseases
关键词
低分子肝素
急性脑梗死
安全性
Low molecular weight heparim Acute cerebral infarction
Safety
